Sol-Gel Technologies Ltd. (SLGL): Cash & Equivalents
$11.03M
As of 2025-12-31
-3.9%
3-year compound annual growth
+9.1%
5-year compound annual growth
+6.5%
10-year compound annual growth
| Period ended | Cash & Equivalents | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $11.03M | -43.4% | 2026-03-19, Balance as of period end |
| 2024-12-31 | $19.49M | +159.4% | 2026-03-19, Balance as of period end |
| 2023-12-31 | $7.51M | -39.6% | 2026-03-19, Balance as of period end |
| 2022-12-31 | $12.45M | -38.0% | 2025-04-29, Balance as of period end |
| 2021-12-31 | $20.09M | +182.0% | 2024-03-13, Balance as of period end |
| 2020-12-31 | $7.12M | -24.3% | 2023-03-10, Balance as of period end |
| 2019-12-31 | $9.41M | +76.8% | 2022-04-07, Balance as of period end |
| 2018-12-31 | $5.33M | +6.0% | 2021-03-04, Balance as of period end |
| 2017-12-31 | $5.02M | -28.2% | 2020-03-24, Balance as of period end |
| 2016-12-31 | $7.00M | +18.8% | 2019-03-21, Balance as of period end |
| 2015-12-31 | $5.89M | n/a | 2018-03-26, Balance as of period end |
Cash & Equivalents at similar companies
| Company | Year ended | Cash & Equivalents | Change YoY |
|---|---|---|---|
| Sol-Gel Technologies Ltd. (SLGL) | 2025-12-31 | $11.03M | -43.4% |
| Evofem Biosciences, Inc. (EVFM) | 2025-12-31 | $578.0K | -22.0% |
| Scynexis Inc (SCYX) | 2025-12-31 | $21.26M | +32.4% |
| CASI Pharmaceuticals, Inc. (CASIF) | 2025-12-31 | $5.63M | -58.2% |
| NewAmsterdam Pharma Co N.V. (NAMS) | 2025-12-31 | $490.00M | -36.5% |
| uniQure N.V. (QURE) | 2025-12-31 | $80.24M | -49.5% |
| Alumis Inc. (ALMS) | 2025-12-31 | $89.67M | -47.1% |
| Entrada Therapeutics, Inc. (TRDA) | 2025-12-31 | $90.39M | -10.7% |
| Opus Genetics, Inc. (IRD) | 2025-12-31 | $45.09M | +48.7% |
Compare SLGL, EVFM, SCYX, CASIF side by side · Screen every company in Pharmaceutical Preparations ↗